In a recent study using murine models of HCC, it was shown that this combination therapy reprogrammed the TME by increasing cytotoxic CD8 T cell, while reducing Treg infiltration in HCC tissue and shifting the M1/M2 macrophages ratio in favor of antitumoral TME [158]. This evidence concerns the gene CD8A and hepatocellular carcinoma.